Cache Valley Virus

Overview and Taxonomy of Cache Valley Virus

Taxonomic Classification and Genomic Architecture

Cache Valley virus (CVV) is a mosquito-borne arbovirus assigned to the genus Orthobunyavirus within the family Peribunyaviridae, order Bunyavirales (formerly the Bunyaviridae family) [1, 2, 3]. This taxonomic placement situates CVV within a large and diverse group of enveloped, negative-sense, single-stranded RNA viruses that are among the most significant emerging zoonotic and veterinary pathogens globally. The order Bunyavirales encompasses nine families, with Peribunyaviridae representing a critical lineage that includes numerous arthropod-borne viruses capable of causing severe disease in both humans and livestock [2]. The genus Orthobunyavirus itself is further subdivided into serogroups based on antigenic relationships, with CVV belonging to the Bunyamwera serogroup, a complex of viruses that exhibit extensive serological cross-reactivity [1, 4]. This serogroup affiliation is not merely a taxonomic convenience; it has profound implications for diagnostic specificity and the interpretation of serosurveillance data, as antibodies against one member can confound the detection of another [4].

Structurally, the CVV virion is spherical, approximately 80–120 nm in diameter, and characterized by a tripartite genome consisting of three single-stranded, negative-sense RNA segments designated small (S), medium (M), and large (L) [1, 3]. The S segment encodes the nucleocapsid (N) protein and a nonstructural protein (NSs) in an overlapping open reading frame. The NSs protein is a recognized virulence factor that functions as a potent antagonist of the host type I interferon (IFN) response [5]. Intriguingly, the interferon-suppressive role of NSs has been experimentally demonstrated through the generation of recombinant CVV lacking the NSs open reading frame, which induces robust IFN production and is markedly attenuated in vertebrate cells [5]. This molecular mechanism underscores a critical evolutionary strategy: CVV, like many orthobunyaviruses, relies on NSs-mediated subversion of innate immunity to establish productive infection in mammalian hosts, a feature that is central to its pathogenesis and a target for rational vaccine design [6, 7].

The M segment encodes a polyprotein that is post-translationally cleaved into two envelope glycoproteins (Gn and Gc) and a second nonstructural protein (NSm) [1, 6]. Gn and Gc are integral for receptor binding and membrane fusion, mediating viral entry into host cells and determining vector specificity. The functional significance of NSm is less fully elucidated, but deletion of NSm in conjunction with NSs yields a highly attenuated live vaccine candidate (2delCVV) that demonstrates reduced replication in both vertebrate cells and mosquito vectors [6, 7]. The L segment encodes the viral RNA-dependent RNA polymerase (RdRp), the enzymatic machinery responsible for genome replication and transcription [3]. This polymerase is a primary target for antiviral drug development; high-throughput screening of small molecules against CVV has identified compounds that inhibit replication by targeting RdRp activity, as demonstrated using minigenome reporter assays [3].

Genetic Diversity and Lineage Dynamics

Phylogenetic analyses of CVV isolates, based primarily on complete genome sequencing of the S, M, and L segments, have revealed the existence of at least two distinct viral lineages circulating in North America [8, 9]. Lineage 1 comprises historical isolates, including the prototype strain originally recovered from Culiseta inornata mosquitoes in Cache Valley, Utah, in 1956 [8, 4]. Lineage 2 encompasses more recently circulating strains, including those associated with human neuroinvasive disease and contemporary epizootics in ruminants [8]. Importantly, molecular surveillance conducted in New York State over a 16-year period (2000–2016) documented a marked temporal shift in lineage prevalence: lineage 1 strains were progressively displaced by lineage 2 strains, a phenomenon that correlates with increased vector competence in Anopheles quadrimaculatus mosquitoes for lineage 2 isolates [8]. This lineage displacement is not merely an academic observation; it signifies a functional evolutionary change that may enhance transmission efficiency and alter the epizootic potential of the virus.

Further complicating the genetic landscape of CVV is the occurrence of segment reassortment, a common evolutionary mechanism among segmented viruses [8, 9, 10]. Reassortment involves the exchange of entire genome segments between two distinct viruses co-infecting the same host cell, leading to the emergence of novel strains with hybrid genetic constellations. Evidence for reassortment among CVV strains has been documented in both mosquito and human isolates. For instance, a reassortant CVV strain (PA) was isolated from a human patient in Pennsylvania, and genomic characterization revealed that this strain possessed a divergent M segment derived from a different orthobunyavirus lineage [9, 10]. Similarly, a second reassortant (15041084) was identified from mosquito pools, and comparative sequence analysis of the two reassortants demonstrated 0.3%, 0.4%, and 0.3% divergence at the nucleotide level for the S, M, and L segments, respectively, with correspondingly low numbers of amino acid differences [9]. Despite the genetic similarity between these reassortants, they exhibited striking phenotypic differences: the human-derived PA strain was attenuated in both vertebrate (Vero) and mosquito (C6/36) cell cultures, and critically, it failed to disseminate from the midgut in Aedes albopictus, rendering it non-transmissible by this vector [9]. Conversely, the mosquito-derived reassortant 15041084 and a lineage 2 strain (Hu-2011) were efficiently transmitted by Ae. albopictus, with transmission rates ranging from 27.3% to 62.1% [9]. These data vividly illustrate that reassortment can generate viruses with dramatically altered ecological fitness and zoonotic potential.

Ecology, Vectors, and Sylvatic Transmission

CVV perpetuates in an enzootic cycle involving mosquito vectors and vertebrate amplifying hosts, with occasional spillover into humans and domestic livestock [1, 11, 2]. The sylvatic transmission cycle is complex and maintained by multiple mosquito species across diverse ecological niches. Ecological niche modeling, combined with background similarity tests, has identified Aedes vexans, Culiseta inornata, and Culex tarsalis as the most probable enzootic vectors, while the white-tailed deer (Odocoileus virginianus) emerges as a primary mammalian reservoir host [11]. This deer–mosquito cycle likely sustains CVV transmission in rural and peri-urban landscapes throughout North America. The geographic range of suitable CVV habitat, as predicted by ecological models, is continental in scale, encompassing large swaths of the United States, Canada, Mexico, and Central America, with significant hotspots of transmission risk that have not yet been confirmed by active surveillance [11]. This mismatch between predicted and observed distribution suggests substantial underreporting and misdiagnosis of CVV infections.

Vector competence studies have greatly expanded our understanding of which mosquito species can transmit CVV. Laboratory colonization and oral feeding experiments have established that Ae. albopictus is a highly efficient vector, exhibiting high infection rates, rapid dissemination, and robust transmission in saliva [12, 13]. This finding is alarming given the global expansion of Ae. albopictus as an invasive species. First detected in CVV surveillance in New York State in 2017–2020, the presence of Ae. albopictus in temperate regions introduces an anthropophilic bridge vector capable of linking the enzootic cycle to human populations [9, 12]. Aedes aegypti, another anthropophilic species, is significantly less susceptible to CVV infection, displaying lower infection frequencies and delayed replication kinetics, but remains capable of transmission under laboratory conditions [12]. Among Culex species, only Cx. tarsalis is a competent vector, whereas Cx. pipiens and Cx. quinquefasciatus are highly refractory to infection [14]. Aedes japonicus japonicus, a widely distributed invasive mosquito in the Appalachian region of the United States, has also been shown to transmit CVV in laboratory trials, and viral RNA has been detected in field-collected specimens [15, 13]. Collectively, these data indicate that CVV is vectored by a broad and ecologically diverse assemblage of mosquitoes, which enhances its capacity to persist across varied habitats and to emerge in new geographical regions.

Historical Context and Emerging Significance

CVV was first isolated in 1956 from Culiseta inornata mosquitoes collected in the Cache Valley of Utah, an event that gave the virus its name [1, 4]. For decades following its discovery, CVV was considered an obscure arbovirus of little consequence to human or animal health. This perception began to change dramatically in the late 1980s and early 1990s when CVV was identified as the etiological agent of devastating epizootics of congenital malformations in sheep flocks across the United States, particularly in Texas [16, 17]. These outbreaks were characterized by fetal death, arthrogryposis, hydranencephaly, scoliosis, and kyphosis, resulting in substantial agroeconomic losses [18, 19, 20, 21, 16]. Experimental inoculation of pregnant ewes with CVV isolate CK-102 between 27 and 54 days of gestation reproduced these malformations in 28 of 34 fetuses, definitively establishing the virus's teratogenic potential [16]. The critical window of susceptibility corresponds to the first trimester, a period of organogenesis during which the developing fetal central nervous system and musculoskeletal system are exquisitely vulnerable to viral insult [2, 16].

Since these initial discoveries, CVV has been implicated in congenital disease outbreaks in sheep and goats across a growing geographic area, including Alabama, Arkansas, Ontario (Canada), and the south-central Appalachian region [18, 22, 23, 24, 20]. Seroprevalence studies in sheep have documented infection rates ranging from 8.6% to 71.9% in enzootic areas of Texas, 33.2% in Ontario, and widespread seropositivity in the southeastern United States [23, 24, 17]. A One Health investigation in Arkansas in 2023 detected CVV RNA in an aborted lamb, prompting integrated surveillance across animal health, public health, and entomology sectors [22, 19]. These studies highlight that CVV is an endemic and economically significant pathogen of small ruminants, yet it remains underdiagnosed due to the subclinical nature of infections in adult animals and the lack of routine diagnostic testing [19].

The recognition of CVV as a zoonotic pathogen capable of causing severe human disease represents a more recent and troubling development. As of 2023, fewer than a dozen human cases have been documented in the peer-reviewed literature, but this low number almost certainly reflects profound underdiagnosis rather than true rarity [1, 2, 25]. Human infections can manifest as a febrile illness with leukopenia and thrombocytopenia, progressing to meningoencephalitis, particularly in immunocompromised individuals [1, 26, 10, 27, 28]. The index human case was identified retrospectively in 2003, and subsequent cases have been reported in Missouri, New York, and other states [26, 10, 29, 27, 25]. Notably, a kidney transplant recipient acquired CVV via transfusion of contaminated red blood cells, demonstrating that non-vector-borne transmission is possible and raising concerns for blood safety [26]. An adolescent with an IKZF1/Ikaros immunodeficiency developed meningoencephalitis and was treated with molnupiravir, an antiviral agent associated with clearance of CVV from the cerebrospinal fluid [30]. These cases underscore that CVV is a rare but important cause of neuroinvasive disease in patients with hematologic malignancies, those receiving B-cell-depleting therapies such as rituximab, and solid organ transplant recipients [26, 29, 27]. The Centers for Disease Control and Prevention (CDC) and the World Organisation for Animal Health (WOAH) have recognized CVV as an emerging arbovirus of public health and veterinary importance, yet it remains without a licensed vaccine or specific antiviral therapy for human or agricultural use, a critical gap that demands urgent research attention [1, 2, 3].

Molecular Virology and Pathogenesis of Cache Valley Virus

Cache Valley virus (CVV) is a tri-segmented, negative-sense, single-stranded RNA virus belonging to the genus Orthobunyavirus within the family Peribunyaviridae, order Bunyavirales [1, 2]. First isolated in 1956 from a Culiseta inornata mosquito in Cache Valley, Utah, CVV has since been recognized as a significant emerging arboviral pathogen with a complex molecular biology that underpins its diverse pathogenic mechanisms in both ruminant and human hosts [1, 4]. The virus possesses a genome architecture typical of orthobunyaviruses, comprising three RNA segments: the large (L) segment, the medium (M) segment, and the small (S) segment [1, 5]. The L segment encodes the RNA-dependent RNA polymerase (RdRp), a multifunctional enzyme responsible for viral genome replication and mRNA transcription [3, 5]. The M segment encodes a single polyprotein that is co-translationally cleaved into the two surface glycoproteins, Gn and Gc, and a nonstructural protein, NSm [6, 7]. The S segment employs an ambisense coding strategy, producing the nucleocapsid (N) protein and another nonstructural protein, NSs [6, 5]. This genomic organization is central to the virus's ability to evade host immune responses, replicate efficiently in diverse cell types, and cause severe pathology.

Genomic Organization and Protein Function

The molecular pathogenesis of CVV is inextricably linked to the functions of its encoded proteins, particularly the nonstructural proteins NSs and NSm, which act as key virulence factors. The NSs protein, encoded by the S segment, is a potent antagonist of the host type I interferon (IFN) system [5]. Mechanistically, NSs inhibits host cell transcription and blocks the induction of IFN-β, thereby crippling the innate antiviral response. Studies using reverse genetics to generate recombinant CVV lacking NSs expression (ΔNSs) have demonstrated that this protein is essential for virulence; ΔNSs viruses induce robust IFN production and are significantly attenuated in both cell culture and animal models [5]. This function is conserved across many orthobunyaviruses, positioning NSs as a primary determinant of host range and pathogenicity. The NSm protein, derived from the M segment polyprotein, has been implicated in viral morphogenesis and, importantly, in the suppression of apoptosis in infected cells [6, 7]. Deletion of NSm, particularly in combination with NSs deletion (2delCVV), results in profound attenuation, not only in vertebrate hosts but also in mosquito vectors, where replication is reduced by over 100-fold [6, 7]. This dual attenuation makes the NSs/NSm deletion strategy a highly promising platform for developing live-attenuated vaccine candidates, as it minimizes the risk of reversion to virulence and vector-borne transmission [6, 7].

The surface glycoproteins, Gn and Gc, are critical for receptor binding, membrane fusion, and viral entry. Gc is considered the major fusion protein, while Gn is likely involved in receptor attachment [1]. The M segment also exhibits significant genetic plasticity, as evidenced by the frequent occurrence of segment reassortment, a process that can drive viral emergence and alter pathogenic potential [8, 10]. Phylogenetic analyses have identified two distinct CVV lineages (lineage 1 and lineage 2) circulating in North America, and evidence suggests that lineage 2 has displaced lineage 1 in regions such as New York and Canada [8]. This displacement may be linked to differences in vector competence, as Anopheles quadrimaculatus mosquitoes show enhanced susceptibility to lineage 2 strains [8]. Furthermore, the detection of naturally occurring reassortant CVV strains, such as the PA isolate from a human case in Missouri, underscores the capacity for segment exchange to generate novel genotypes with altered virulence and tissue tropism [9, 10]. The PA reassortant, for instance, was found to be attenuated in both vertebrate and mosquito cell lines and failed to disseminate from the midgut of Aedes albopictus, highlighting how reassortment can produce phenotypically diverse viruses [9].

Host Range, Cellular Tropism, and Species Susceptibility

CVV exhibits a remarkably broad host range, infecting a wide array of mammalian species and utilizing numerous mosquito genera as vectors [11, 2]. In nature, the virus is maintained in an enzootic cycle primarily between mosquitoes and white-tailed deer (Odocoileus virginianus), which are considered the principal amplifying vertebrate hosts [11, 15]. Ecological niche modeling has identified Aedes vexans, Culiseta inornata, and Culex tarsalis as the most likely enzootic vectors, while Aedes albopictus, Aedes aegypti, and Aedes japonicus have been demonstrated to be competent bridge vectors capable of transmitting CVV to humans and livestock [11, 12, 15, 14]. The vector competence of these species is highly variable and dose-dependent; for example, Ae. albopictus shows high susceptibility and transmission rates (up to 68%) when fed a high-titer blood meal, whereas Ae. aegypti is significantly less competent [12, 13]. Culex tarsalis is another competent vector, while Culex pipiens and Culex quinquefasciatus are highly refractory to infection [14]. This differential vector competence is a critical determinant of CVV's geographic distribution and its capacity to spill over into human and domestic animal populations.

In vertebrate hosts, CVV demonstrates a wide cellular and tissue tropism. In experimentally infected IFN-αβR-/- mice, which lack a functional type I IFN response, CVV replicates to high titers in the liver, spleen, and placenta, causing lethal disease with minimal age-dependent differences [31]. This model underscores the absolute requirement of the innate immune system for controlling CVV infection. In immune-competent mice, infection is generally subclinical, with disease only manifesting in an age-dependent manner, likely due to the maturation of the IFN system [31]. In ruminants, the primary target for CVV-induced pathology is the developing fetus. Experimental in utero inoculation of sheep fetuses between 27 and 54 days of gestation results in a high incidence (82%) of congenital malformations, including arthrogryposis, hydranencephaly, and fetal mummification [16]. The virus replicates efficiently in fetal tissues, particularly the central nervous system (CNS), and can be isolated from allantoic fluid up to 70 days of gestation [16]. The development of fetal neutralizing antibodies after 76 days correlates with viral clearance, suggesting that the fetal immune response, once mature, can control infection [16]. In adult ruminants, infection is typically subclinical, although CVV has been isolated from a clinically normal horse and, more recently, associated with disease in a horse from Mexico, expanding the known clinical spectrum [32, 33].

Pathogenesis in Ruminants: Teratogenesis and Reproductive Failure

The most economically significant manifestation of CVV infection is its potent teratogenic effect in pregnant sheep and goats, a phenomenon that has been documented in numerous outbreaks across North America [1, 18, 19, 23, 20, 17]. Infection of a naive ewe during the first trimester, specifically between days 28 and 50 of gestation, when the fetal CNS and musculoskeletal systems are undergoing rapid development, leads to a characteristic syndrome of congenital malformations [2, 21, 16]. The hallmark lesions include arthrogryposis (persistent flexure of joints), kyphosis, scoliosis, hydranencephaly (replacement of cerebral hemispheres with fluid-filled sacs), cerebellar hypoplasia, and marked atrophy of the spinal cord [18, 20, 21, 16]. These defects are the direct result of viral replication and cytopathic effects in the developing fetal neurons and glial cells, leading to necrosis and subsequent failure of normal brain and spinal cord development. The severity of the malformations is inversely correlated with the gestational age at the time of infection; earlier infections tend to cause more severe, often lethal, defects, while later infections may result in milder or subclinical outcomes [16].

The pathogenesis of CVV-induced abortion and fetal death is multifactorial. Direct viral damage to the placenta and fetal membranes can lead to placental insufficiency and fetal hypoxia [31]. In the murine model, CVV shows significant amplification in placental tissues, resulting in high rates of in utero transmission, spontaneous abortions, and congenital malformations [31]. In sheep, infection can lead to embryonic loss, mummification, and resorption, often without any overt clinical signs in the ewe [19, 16]. The economic impact on the sheep and goat industry is substantial, with studies estimating that CVV infection during pregnancy can reduce the number of live lambs born by 18% and those weaned by 27% [19]. Seroprevalence studies in sheep flocks across the United States and Canada have revealed widespread exposure, with rates ranging from 8.6% to 71.9% in Texas and 33.2% in Ontario, Canada [23, 17]. Risk factors for seropositivity include increased age, smaller flock size, and housing near wetlands, lakes, or ponds, which are habitats for competent mosquito vectors [23]. The World Organisation for Animal Health (WOAH) recognizes CVV as a significant cause of ovine congenital malformations, and it is considered a differential diagnosis for any outbreak of arthrogryposis-hydranencephaly syndrome in lambs and kids [18, 21].

Pathogenesis in Humans: Neuroinvasion and Immunocompromise

Human infection with CVV is considered rare, but the true incidence is likely underestimated due to misdiagnosis and a lack of routine testing [1, 2, 25]. As of the most recent reports, fewer than a dozen human cases have been definitively documented, yet seroprevalence studies indicate that exposure is relatively common in endemic areas, with neutralizing antibodies detected in residents of several Latin American cities [1, 12]. The clinical spectrum of human CVV disease ranges from a mild, self-limiting febrile illness to severe, life-threatening neuroinvasive disease [10, 2, 28]. The first recognized human case was reported in 2006, and subsequent cases have included acute febrile illness with leukopenia and thrombocytopenia, as well as meningoencephalitis [10, 25, 28]. A pivotal case in 2020 demonstrated that CVV can be transmitted via blood transfusion, leading to severe meningoencephalitis in a kidney transplant recipient, highlighting the risk to immunocompromised populations [26].

The molecular basis for neuroinvasion in humans is not fully understood, but it is clear that the host immune status is a critical determinant. The majority of severe human cases have occurred in individuals with underlying immunocompromising conditions, such as chronic lymphocytic leukemia (CLL) treated with rituximab, or primary immunodeficiencies like IKZF1/Ikaros deficiency [30, 29, 27]. Rituximab, a monoclonal antibody that depletes B cells, profoundly impairs humoral immunity, and its use has been associated with fatal CVV meningoencephalitis [27]. Similarly, the first pediatric case of CVV encephalitis occurred in an adolescent with a genetic immunodeficiency affecting the Ikaros family of transcription factors, which are essential for lymphocyte development [30]. In these patients, the inability to mount an effective neutralizing antibody response allows the virus to disseminate from the periphery to the CNS, where it establishes a persistent infection. Metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) has proven invaluable for diagnosing CVV encephalitis in such cases, as conventional serological and PCR-based tests may be negative [26, 29]. The virus can be detected in CSF by RT-PCR, viral culture, and mNGS, and the presence of CVV RNA in the CSF is associated with a poor prognosis [26, 30]. The pathogenesis of CVV neuroinvasive disease likely involves direct viral replication in neurons and glial cells, leading to neuronal death, inflammation, and the characteristic findings of lymphocytic pleocytosis and elevated protein in the CSF [27, 25]. The potential for CVV to act as a human teratogen remains an open question; a study of women who gave birth to infants with neural tube defects in Texas found no evidence of CVV neutralizing antibodies, but this does not rule out the possibility during epidemic periods [34]. The U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) consider CVV an emerging arboviral threat, and ongoing surveillance is critical to define its full public health impact [1, 28].

Molecular Mechanisms of Immune Evasion and Viral Persistence

The ability of CVV to establish infection and cause disease is largely dependent on its sophisticated immune evasion strategies. As previously noted, the NSs protein is the primary antagonist of the type I IFN response, acting by inhibiting host cell transcription and blocking the activation of IFN regulatory factors [5]. This allows the virus to replicate to high titers before the host can mount an effective antiviral state. In immunocompetent individuals, the IFN response is ultimately able to control infection, but in immunocompromised hosts, this barrier is absent, leading to uncontrolled viral replication and dissemination [27, 31]. The NSm protein contributes to immune evasion by inhibiting apoptosis, thereby prolonging the survival of infected cells and allowing for continued viral production [6, 7]. Furthermore, the virus can establish persistent infections in certain cell types, as evidenced by the chronic meningoencephalitis observed in immunodeficient patients [29]. In the murine model, CVV can be detected in the CNS for extended periods, suggesting that the virus has mechanisms to evade clearance even in the presence of an adaptive immune response [31]. The high degree of genetic variability, driven by both genetic drift and segment reassortment, also contributes to immune evasion by allowing the virus to rapidly alter its antigenic profile [8, 10]. The development of monoclonal antibodies (MAbs) against the CVV nucleoprotein has been crucial for diagnostic development, but these MAbs are non-neutralizing, highlighting the challenge of generating effective humoral immunity against this virus [4]. The interplay between viral virulence factors, host genetics, and immune status ultimately determines the outcome of CVV infection, ranging from asymptomatic seroconversion to fatal encephalitis or severe fetal malformations.

Ecology and Geographic Distribution of Cache Valley Virus

Cache Valley virus (CVV) exemplifies a mosquito-borne orthobunyavirus with a remarkably broad ecological amplitude, occupying diverse biomes across the Americas from temperate North America through tropical Central America and into parts of South America [1, 2]. The virus persists through an enzootic cycle involving mosquito vectors and vertebrate amplifying hosts, primarily white-tailed deer, with periodic spillover into livestock and humans [11, 2]. Understanding the intricate ecological niche of CVV is foundational to predicting emergence events and mitigating both agricultural losses and human disease.

Sylvatic Transmission Cycle and Principal Vectors

The maintenance of CVV in nature depends upon a complex web of mosquito species capable of supporting viral replication and transmission. The virus was first isolated in 1956 from Culiseta inornata in Cache Valley, Utah, establishing the historical association with this species [1, 4]. However, contemporary ecological niche modeling and extensive field surveillance have identified a more diverse vector community than previously recognized. Background similarity tests combining locality data for CVV isolations with climatic variables and vector occurrence have identified Aedes vexans, Culiseta inornata, and Culex tarsalis as the most statistically likely species sustaining sylvatic transmission across North America [11]. These findings are corroborated by vector competence studies demonstrating that Cx. tarsalis can become infected per os and transmit CVV, with viral RNA detected in saliva, confirming its role as a competent bridge vector [14].

The importance of Anopheles mosquitoes in CVV ecology has been increasingly recognized. Surveillance in New York State from 2000 to 2016 revealed the highest maximum-likelihood infection rates among Anopheles spp. mosquitoes, surpassing those of other genera [8]. Critically, An. quadrimaculatus demonstrated significantly higher vector competence for lineage 2 strains compared to lineage 1 strains, providing a mechanistic explanation for the observed displacement of lineage 1 by lineage 2 in the northeastern United States and Canada [8]. This finding underscores how vector ecology can drive pathogen evolution at a continental scale.

Geographic Distribution and Range Expansion

CVV circulates throughout a vast geographic expanse that includes Canada, the United States, Mexico, Central America, and parts of South America [1, 2]. Ecological niche modeling incorporating climatic variables, vector distributions, and host occurrence has produced distribution maps demonstrating a continental-level potential for viral occurrence across North America [11]. The models identify large areas with suitable climate, vectors, and hosts for CVV emergence, establishment, and spread, including regions with no confirmed CVV reports to date, suggesting substantial underreporting or misdiagnosis [11].

Seroprevalence surveys provide granular evidence of the virus's extensive distribution. In Ontario, Canada, a cross-sectional study of 364 ewes across 18 farms found a seroprevalence of 33.2% (95% CI: 28.4%–38.1%), with 88.9% of flocks harboring at least one seropositive animal [23]. In Texas, seroprevalence in sheep fluctuated dramatically between years, ranging from 8.6% to 71.9% in a sentinel flock at the Texas Agricultural Experiment Station in San Angelo, reflecting enzootic transmission with periodic epizootic amplification [17]. Longitudinal sampling in this same flock captured the dynamics of CVV transmission, with seroprevalence peaking at 63.4% in 1987 following the initial outbreak of congenital malformations, declining to 11.3% in 1988, and rebounding to 71.9% in 1989 [17]. These data indicate that CVV is not uniformly distributed but exhibits focal hotspots of intense transmission.

Recent emergence events signal a geographic expansion of CVV. In 2023, CVV RNA was detected in an aborted lamb in Arkansas, prompting a One Health investigation that revealed broader circulation in the state [22, 19]. In 2024, serological identification of CVV in a teaching flock at Auburn University in Alabama confirmed infection in ewes that produced lambs with severe arthrogryposis, kyphosis, scoliosis, hydrocephalus, and cerebellar hypoplasia [18]. This case series is clinically significant because Alabama had not been considered a historically endemic region, demonstrating that the virus is expanding its range or its detection is improving through increased awareness [18]. In Mexico, CVV was isolated for the first time from a clinically affected horse in Veracruz State, along the Gulf coast, representing the first association between CVV and equine disease and extending the known host range and geographic footprint in Latin America [32].

Vertebrate Hosts and Amplification

The sylvatic cycle of CVV depends upon competent vertebrate reservoirs that develop sufficient viremia to infect feeding mosquitoes. Ecological niche modeling and background similarity tests have identified Odocoileus virginianus (white-tailed deer) as the most likely host sustaining sylvatic transmission [11]. This conclusion is supported by extensive evidence: white-tailed deer are abundant across CVV-endemic regions, are highly attractive to multiple mosquito species, and serosurveys have documented high seroprevalence in deer populations. Indeed, an Appalachian forest study detected CVV in Aedes japonicus japonicus mosquitoes and noted the forest contained abundant white-tailed deer, serving as a major host for both the mosquito and the virus [15].

Sheep and goats serve as incidental, dead-end hosts that do not contribute substantially to enzootic maintenance but suffer devastating consequences when infected during critical gestational windows. Experimental in utero inoculation of sheep between 27 and 54 days of gestation with the CK-102 isolate from Texas produced congenital abnormalities in 28 of 34 fetuses, including arthrogryposis, hydranencephaly, mummification, and reabsorption [16]. Serologic evidence from naturally occurring outbreaks confirms that adult ewes remain clinically healthy while producing severely malformed lambs, a pattern consistent with CVV's tropism for fetal tissues [18, 19, 16].

Bridging Vectors and Spillover to Humans

The mechanisms by which CVV spills over from its sylvatic cycle to infect humans are critical to understanding human disease risk. The zoophilic nature of the primary enzootic vectors (Ae. vexans, Cs. inornata) limits direct transmission to humans, yet human seroprevalence studies have detected neutralizing antibodies in residents of several Latin American cities, indicating frequent exposure [12]. The identification of competent anthropophilic vectors provides a mechanistic explanation. Aedes albopictus, an invasive mosquito species that has spread across the New World, is highly susceptible to CVV, with transmission rates ranging from 16.7% to 62.1% depending on virus strain [9, 12]. In Virginia, Ae. albopictus fed a high-titer CVV blood meal achieved transmission rates of 68%, substantially higher than Ae. aegypti (10%) [13]. The high competence of Ae. albopictus has critical implications for urban and suburban transmission, as this species thrives in peridomestic environments and aggressively bites humans. The first detection of CVV in Ae. albopictus in New York State in 2017–2020 further supports its emerging role as a bridge vector [9].

Aedes japonicus japonicus, another invasive species widely distributed in the Appalachian region, has also yielded CVV isolations in field collections and demonstrated competence in laboratory transmission trials [15, 13]. In contrast, Culex pipiens and Cx. quinquefasciatus are highly refractory to CVV infection, limiting the role of these common urban mosquitoes in transmission [14]. The differential vector competence among mosquito species shapes the spatial epidemiology of CVV, with transmission risk concentrated in areas where competent bridge vectors overlap with amplifying hosts and human populations.

Ecological Drivers of Transmission

Environmental factors exert strong influences on CVV transmission dynamics. In Ontario, farm management factors significantly associated with CVV seropositivity in sheep included increased ewe age, smaller flock size, and housing near wetlands, lakes, or ponds [23]. The proximity to water bodies aligns with the larval habitat requirements of key vectors such as Ae. vexans and Cx. tarsalis, which exploit floodwater and permanent water habitats, respectively. Climatic variables incorporated into ecological niche models, including temperature and precipitation, are major determinants of CVV's potential geographic range, as they directly influence mosquito population dynamics, viral replication rates, and the length of the transmission season [11].

The role of Anopheles mosquitoes in lineage displacement in New York provides an elegant example of how vector competence can shape viral population genetics at the landscape level. The documented displacement of lineage 1 by lineage 2 was accompanied by evidence that An. quadrimaculatus mosquitoes are more competent vectors for lineage 2 strains [8]. This phenomenon suggests that vector species composition can exert selective pressure on circulating CVV strains, potentially altering the transmission efficiency, virulence, or geographic distribution of specific lineages. Given that lineage 2 now predominates in the northeastern United States, the ecological implications for spillover risk to livestock and humans warrant continued surveillance.

Epidemiology and Seroprevalence in Humans and Animals

Cache Valley virus (CVV) represents one of the most understudied yet geographically widespread arboviruses in the Americas, occupying a unique ecological niche that bridges enzootic sylvatic cycles with significant spillover potential into both human and domestic animal populations. Despite its initial isolation from Culiseta inornata mosquitoes in Utah in 1956, the virus has remained largely neglected by the broader scientific community, a phenomenon that has perpetuated profound gaps in our understanding of its true burden, spatial distribution, and transmission dynamics [1, 11]. The epidemiology of CVV is uniquely characterized by a sharp dichotomy: it is a well-documented, economically devastating teratogen in sheep and goats, yet a cryptic, sporadically diagnosed pathogen in humans, where only a handful of cases have been formally recognized since its discovery [1, 2]. This disparity almost certainly reflects ascertainment bias and diagnostic under-utilization rather than a genuine absence of human infection, given the mounting serological evidence demonstrating widespread human exposure across North and Central America [12, 35].

Human Seroprevalence and Documented Infections

The available data on human CVV infection are startlingly sparse, yet they collectively paint a picture of a pathogen with a far broader footprint than currently appreciated. As of the most recent comprehensive reviews, fewer than ten human cases of CVV-associated disease have been definitively documented in the peer-reviewed literature, with the first case recognized only relatively recently [2, 25]. The index case, reported in 2006, involved a previously healthy adult who developed neuroinvasive disease, and subsequent reports have expanded the clinical spectrum to include acute febrile illness, meningoencephalitis, and, notably, transmission via blood transfusion in an immunocompromised kidney transplant recipient [26, 10, 25]. This latter case is particularly illuminating, as it underscores the potential for non-mosquito-borne transmission of CVV and raises critical safety considerations for blood banking practices in endemic regions [26].

However, the most compelling evidence for widespread human exposure comes not from case reports but from targeted serosurveys. A pivotal study leveraging a newly developed IgM antibody capture ELISA (MAC-ELISA) screened archived serum samples from febrile patients in Yucatán, Mexico, who had previously tested negative for common flaviviral and alphaviral infections. Remarkably, two of 27 such samples (7.4%) tested positive for anti-CVV IgM, and these results were corroborated by plaque reduction neutralization testing (PRNT), providing strong evidence of recent, acute CVV infection in a region where the virus was not previously considered a major cause of human febrile illness [35]. This finding suggests that CVV may be a significant, unrecognized contributor to undifferentiated febrile syndromes across Latin America, a hypothesis supported by earlier studies detecting high prevalence rates of neutralizing antibodies among residents of several Latin American cities [12, 25]. Furthermore, ecological niche modeling has identified vast swaths of North America, including the southeastern United States, the Mississippi River Valley, and regions stretching through Central America, as possessing climate, vector, and host assemblages highly suitable for CVV transmission, yet many of these areas have no confirmed human case reports [11]. This mismatch between predicted risk and confirmed diagnosis is a hallmark of an underreported pathogen.

The question of whether CVV acts as a human teratogen remains unresolved and is one of the most critical gaps in the epidemiological literature. Following the recognition of CVV's devastating teratogenic effects in ruminants, a targeted investigation was conducted in south Texas during the early 1990s, a region that had experienced an outbreak of neural tube defects, including anencephaly. Sera from 74 women who had given birth to infants with neural tube defects were tested for CVV neutralizing antibodies; all were negative [34]. While this study provides reassurance that CVV is not a common cause of these specific malformations during non-epidemic periods, it does not preclude the possibility of teratogenic effects during CVV outbreaks or in cases of infection at other critical gestational windows, nor does it rule out the involvement of other Bunyaviruses. The lack of routine CVV testing in pregnant women with fever or rash illness remains a critical data void [1, 34].

Animal Seroprevalence and Epizootiology

In stark contrast to the limited human data, the veterinary epidemiological literature on CVV is considerably more robust, driven primarily by the virus's profound impact on the sheep industry. CVV is now recognized as a major cause of embryonic death, fetal resorption, stillbirth, and severe congenital malformations, including arthrogryposis, hydranencephaly, cerebellar hypoplasia, and kyphoscoliosis, in sheep and goats. These outcomes occur when pregnant ewes are infected during a critical window of gestation, typically between 27 and 50 days, a period coinciding with organogenesis [18, 22, 20, 16]. The economic consequences for producers can be catastrophic, with documented reductions in the number of live lambs born by 18% and those weaned by 27% in affected flocks [19].

Seroprevalence surveys across North America have consistently demonstrated widespread CVV circulation in small ruminant populations, with rates varying significantly by geographic location, management practices, and temporal factors. In the United States, early investigations in Texas revealed that 19.1% of 366 sheep from 22 counties were seropositive in 1981, while longitudinal sampling at the Texas Agricultural Experiment Station in San Angelo, the site of a major 1987 epizootic, showed dramatic year-to-year fluctuations in seroprevalence: 8.6% in 1986, spiking to 63.4% in 1987, dropping to 11.3% in 1988, and rising again to 71.9% in 1989 [17]. This marked interannual variability is characteristic of arboviral diseases influenced by fluctuating vector populations, weather patterns, and herd immunity. A more recent case series from Alabama in 2024 reported that all six ewes in a teaching flock with exposed to a CVV-infected environment were seropositive, while the ram tested negative, underscoring the high attack rate in susceptible populations [18].

In Canada, a landmark cross-sectional study of 364 ewes across 18 farms in Ontario, the province with the largest sheep population, reported an overall individual-level seroprevalence of 33.2% (95% CI: 28.4%–38.1%), with 88.9% of farms having at least one seropositive animal [23]. This study also provided critical insights into risk factors for CVV exposure, identifying increased ewe age, smaller flock size, and housing sheep near wetlands, lakes, or ponds as significant predictors of seropositivity. The association with proximity to water bodies is ecologically coherent, as these habitats support high densities of the mosquito vectors implicated in CVV transmission [11, 23]. In the south-central Appalachian region, a targeted investigation is underway to establish baseline seroprevalence data for a region where anecdotal reports suggest active circulation but formal prevalence estimates are lacking [24].

Beyond sheep, serological and virological evidence of CVV infection has been documented in a diverse array of animal species, underscoring its broad host range. White-tailed deer (Odocoileus virginianus) have been identified as the most likely mammalian host sustaining the sylvatic transmission cycle through ecological niche modeling and field studies, and they are considered a critical amplifying host [11, 15]. Horses also seroconvert, with a study in southwestern Michigan in 1980 finding evidence of enzootic CVV transmission based on age-specific antibody prevalence, and a clinically ill horse in Veracruz, Mexico, yielding the first CVV isolation from this species, associated with neurological disease [32, 33]. Cattle, while less frequently associated with clinical disease, also demonstrate serological evidence of infection. Notably, a large-scale investigation of abortion etiologies in Turkey, which included testing for CVV among other pathogens, found no evidence of CVV RNA in over 1,000 ovine and caprine fetuses, suggesting that CVV may not be present in the Eastern Hemisphere or that its circulation there is extremely limited [36]. This geographic restriction to the Americas is a critical epidemiological feature.

Vectors, Transmission Dynamics, and Geographic Distribution

The epidemiology of CVV is inextricably linked to its vector ecology. The virus has been isolated from a wide array of mosquito species, but recent rigorous ecological niche modeling and vector competence studies have identified the primary epizootic and enzootic vectors. Aedes vexans, Culiseta inornata, and Culex tarsalis have emerged as the most likely species sustaining sylvatic transmission, with Anopheles quadrimaculatus and Anopheles spp. also playing a significant role, particularly in the northeastern United States [11, 8, 14]. Critically, the invasive and highly anthropophilic Aedes albopictus has demonstrated high vector competence for CVV under laboratory conditions, with infection rates and transmission rates (ranging from 16.7% to 62.1%) that are alarmingly efficient [9, 12]. The ability of Ae. albopictus to transmit CVV, combined with its rapid global expansion and its propensity to bite humans in peridomestic settings, provides a mechanistic explanation for how human infections may occur, even in urban and suburban environments far from traditional enzootic foci [12]. In contrast, Aedes aegypti appears to be a less competent vector, and Culex pipiens and Culex quinquefasciatus are highly refractory to infection, suggesting that not all common urban mosquitoes are capable of bridging transmission to humans [12, 14, 13].

Phylogenetic analyses have delineated two major CVV lineages in North America, with compelling evidence of lineage displacement driven by vector competence. In New York State, surveillance data from 2000 to 2016 revealed a shift from lineage 1 to lineage 2, a phenomenon temporally correlated with increased infection rates in Anopheles quadrimaculatus mosquitoes, which demonstrated higher vector competence for lineage 2 strains [8]. This displacement event highlights the dynamic nature of CVV evolution and its potential for changing geographic and host range. Furthermore, the detection of CVV for the first time in Aedes japonicus japonicus, another highly invasive mosquito species, in the Appalachian region further expands the list of competent vectors and suggests that the virus is capable of exploiting new ecological niches as they become available [15].

The geographical distribution of CVV, as predicted by ecological niche modeling, is continental in scale, encompassing most of North America south of the boreal forest, extending through Central America, and reaching into parts of South America [11]. Hotspots of predicted transmission risk, including areas in the southeastern United States, the Great Lakes region, and the Pacific Northwest, align with regions of high white-tailed deer density and suitable mosquito habitat [11]. However, the model also identifies large areas, such as the central Great Plains and parts of the Rocky Mountain region, that are climatically suitable but have no confirmed CVV reports, suggesting that the virus's true range may be even larger than currently documented. The World Organisation for Animal Health (WOAH) recognizes CVV as a pathogen of veterinary significance, and the U.S. Centers for Disease Control and Prevention (CDC) includes CVV among the emerging arboviruses warranting enhanced surveillance and diagnostic capacity [1, 28]. Future investigations, guided by these predictive models, are urgently needed to fill the vast geographic and host-range data gaps that currently define the epidemiology of this emerging pathogen.

Clinical Disease in Ruminants: Teratogenesis and Fetal Death

Cache Valley virus (CVV) stands as one of the most economically significant teratogenic arboviruses affecting ruminant production systems throughout North America. The clinical consequences of CVV infection during gestation represent a stark demonstration of viral teratogenesis, where an otherwise innocuous infection in the adult ewe or doe precipitates catastrophic developmental failure in the developing fetus. The disease is not merely a veterinary curiosity but a substantial threat to sheep and goat production, recognized by the World Organisation for Animal Health (WOAH) as a pathogen of significant concern [1, 2]. The hallmark of CVV-induced clinical disease is the triad of fetal death, severe congenital malformations, and dystocia, occurring in pregnancies where the dam remains entirely asymptomatic throughout infection [1, 18, 19]. This discordance between maternal and fetal outcomes is a defining feature of CVV pathogenesis and underscores the virus's sophisticated mechanism of transplacental invasion and selective tropism for rapidly developing fetal tissues.

Clinical Manifestations in Affected Fetuses and Neonates

The clinical spectrum of disease observed in lambs and kids infected in utero with CVV is remarkably consistent across outbreaks and experimental infections, centering on profound musculoskeletal and central nervous system (CNS) defects. Arthrogryposis, characterized by persistent flexure or contracture of multiple joints, is among the most frequently reported and visually arresting abnormalities [18, 22, 20, 16]. Affected neonates are often non-viable, presenting with rigidly fixed limbs, often in extreme flexion, rendering normal ambulation impossible. This is commonly accompanied by kyphosis and scoliosis, producing dramatic curvature of the spinal column [18]. The underlying pathology is not primarily a bone or joint disease but is instead neurogenic, stemming from severe damage to the developing spinal cord and motor neurons. The Alabama case series documented in 2025 described lambs delivered via Cesarean section that exhibited severe arthrogryposis, kyphosis, and scoliosis, necessitating immediate humane euthanasia [18]. Necropsy of these lambs revealed marked atrophy of the spinal cord concurrent with severe internal hydrocephalus and cerebellar hypoplasia, providing direct anatomical evidence linking CVV infection to destructive lesions in the neural axis [18]. Similarly, a case in Boer goats documented hydranencephaly, a condition where the cerebral hemispheres are largely replaced by fluid-filled sacs, in all three fetuses of a litter recovered via Cesarean section for dystocia [20]. These findings are not isolated; experimental inoculation studies from 1990 demonstrated that 28 of 34 ovine fetuses infected between 27 and 54 days of gestation developed congenital abnormalities, including arthrogryposis, hydranencephaly, fetal mummification, reabsorption, and oligohydramnios [16]. The consistency across decades and geographical regions, from Texas to Alabama to Arkansas, indicates a highly conserved pathogenic mechanism.

The Critical Window of Gestational Susceptibility

A central tenet of CVV teratogenesis is the strict temporal dependence of disease outcome on the gestational stage at which infection occurs. The period of maximal vulnerability for the ovine and caprine fetus lies within the first trimester, specifically between days 27 and 50 of gestation [2, 16]. This window corresponds to the critical phase of organogenesis, particularly the development of the CNS and musculoskeletal systems. Infection prior to or during this period frequently results in fetal death, resorption, or the most severe malformations. The experimental inoculation study by Chung et al. is particularly instructive: fetuses infected at 27 to 50 days of gestation exhibited the full spectrum of abnormalities, including mummification and reabsorption, while two fetuses infected at days 50 and 54 appeared grossly normal, one of which had developed detectable neutralizing antibody against CVV [16]. This suggests that the fetal immune system, once capable of mounting a humoral response, can provide some protection, but this capability develops only after a critical window of vulnerability has passed. In practical terms, this means that breeding schedules that align early gestation with peak mosquito vector activity in late summer and early autumn place flocks at extreme risk. The Arkansas outbreak investigation from 2023, where CVV RNA was detected in an aborted lamb, underscores this seasonal risk, as breeding in August (ram exposure) resulted in seroconversion during pregnancy and subsequent adverse outcomes [22, 19]. Data from this same population estimated that CVV infection during pregnancy resulted in an 18% reduction in the number of live lambs born and a 27% reduction in those weaned, with significant decreases in birth and weaning weights [19].

Fetal Death, Dystocia, and Subclinical Maternal Infection

Perhaps the most insidious aspect of CVV infection in ruminants is the complete absence of clinical signs in the pregnant dam. Ewes and does infected with CVV remain healthy, feed normally, and show no pyrexia or malaise, even as the virus actively replicates in the placenta and fetus [1, 19, 2]. This subclinical presentation means that producers often have no warning of an impending reproductive disaster until term, when dystocia becomes apparent or when dead or deformed lambs are delivered. The economic and welfare implications are severe: dystocia resulting from fetal malformations, such as arthrogrypotic limbs or hydrocephalic heads, necessitates veterinary intervention, often via Cesarean section, and frequently results in fetal demise and maternal stress [18, 20]. The Arkansas sheep flock study spanning 2019–2023 utilized surrogate markers, including embryo loss, birth of dead or deformed lambs, and weak lambs, to estimate an incidence of CVV during pregnancy of 26.5% ± 2.9%, with no significant difference between years or between yearling versus older ewes [19]. This high, consistent incidence over multiple breeding seasons emphasizes the enzootic nature of CVV in certain regions and the persistent threat it poses. In this same study, of 42 ewes bred in August 2022, three (11%) seroconverted between August and October, indicating infection during early pregnancy; two of these had adverse pregnancy outcomes, including one stillbirth with deformities that tested positive by RT-PCR on kidney tissue [19]. The detection of viral RNA in fetal kidney tissue confirms active fetal infection, not merely maternal seroconversion, and provides definitive evidence of transplacental transmission.

Pathogenesis and Mechanisms of Teratogenesis

The biological mechanism underlying CVV's teratogenic effects is rooted in its ability to cross the placenta and establish infection in the highly mitotically active fetal tissues, particularly the developing CNS. The virus exhibits a broad tissue tropism, as demonstrated in murine models, where CVV showed significant amplification in liver, spleen, and placenta tissues [31]. The development of a novel murine in utero transmission model by López et al. in 2021 demonstrated high rates of transplacental transmission, spontaneous abortions, and congenital malformations, providing a tractable small animal model to dissect the pathogenesis [31]. The viral nonstructural protein NSs plays a critical role in pathogenesis by antagonizing the host type I interferon response [5]. Knockout of the NSs gene in recombinant CVV resulted in restoration of interferon production and attenuation of virulence, confirming that NSs is the primary virulence factor enabling unchecked viral replication in susceptible tissues [5]. In the developing fetus, the immature immune system cannot mount an effective interferon response, allowing CVV to replicate unimpeded within neural progenitor cells. This leads to direct cytopathic effects, necrosis, and disruption of the developing architecture of the brain and spinal cord. The resulting lesions, hydranencephaly, porencephaly, cerebellar hypoplasia, and spinal cord atrophy, are the anatomical substrates of the observed clinical deformities [18, 16]. Arthrogryposis arises secondarily from the destruction of ventral horn motor neurons in the spinal cord, leading to neurogenic atrophy and contracture of the associated musculature. The virus can be isolated from allantoic fluid and fetal tissues during the acute phase of infection, but as the fetal immune system matures and neutralizing antibodies appear, virus clearance occurs, typically by day 76 of gestation [16]. This temporal dynamic means that fetal tissues from later-term abortions or stillbirths may be virus-negative, complicating definitive diagnosis by molecular methods; serological testing of fetal fluids or pre-colostral serum may be required to confirm infection.

Diagnostic Confirmation and Differential Diagnosis

Given the subclinical nature of maternal infection and the non-specific presentation of late-term abortion or fetal malformation, laboratory confirmation is essential for accurate diagnosis. The plaque reduction neutralization test (PRNT) remains the gold standard for serological detection of CVV-specific neutralizing antibodies in both maternal and fetal sera, with a titer of ≥1:10 considered positive [19, 4]. However, PRNT requires live virus, is time-consuming, and cannot differentiate recent from past infections [35]. For fetal diagnosis, RT-PCR targeting conserved regions of the CVV genome, such as the G1 glycoprotein or nucleocapsid sequences, provides rapid, specific detection of viral RNA in fetal tissues, placenta, or allantoic fluid [19, 37]. The duplex real-time RT-PCR assay developed by Wang et al. in 2009 can detect both CVV and California serogroup viruses simultaneously, with a sensitivity of 30 gene copies per reaction for CVV, making it a powerful tool for surveillance and outbreak investigation [37]. In the Arkansas investigation, fetal kidney tissue from a stillborn lamb with deformities tested positive via CVV-specific RT-PCR, confirming active viral infection [19]. Importantly, maternal seropositivity alone is not diagnostic of fetal infection, as it may reflect past exposure rather than current pregnancy-related infection. A definitive diagnosis of CVV-induced fetal disease requires either detection of viral RNA or antigen in fetal tissues, or demonstration of specific neutralizing antibody in fetal serum or fluids obtained prior to colostrum ingestion [19, 16]. The Centers for Disease Control and Prevention (CDC) has developed a CVV-specific IgM antibody capture ELISA (MAC-ELISA) for human diagnosis, and while primarily intended for public health use, the principles could be adapted for veterinary applications, particularly for detecting recent infections in pregnant ewes [35].

Epidemiological Context and Geographic Distribution

CVV-induced clinical disease in ruminants has been documented across a broad geographical range, with confirmed outbreaks and serological evidence extending from Canada to the southern United States. A cross-sectional study of 364 mature ewes across 18 farms in Ontario, Canada, found a seroprevalence of 33.2% at the individual level, with 88.9% of flocks harboring at least one seropositive ewe [23]. This study identified risk factors significantly associated with CVV seropositivity: increased age, smaller flock size, and housing sheep near wetlands, lakes, or ponds [23]. The association with proximity to water bodies is ecologically intuitive, as these habitats support larval development of key mosquito vectors, particularly Aedes vexans, Culiseta inornata, and Anopheles species [11, 8, 14]. In Texas, a landmark study from the late 1980s demonstrated that 19.1% of 366 sheep across 22 counties had CVV-specific antibodies, and that seroprevalence at the Texas Agricultural Experiment Station in San Angelo fluctuated dramatically between years, from 8.6% in 1986 to 63.4% in 1987 during the height of an outbreak [17]. This variability underscores the epizootic nature of CVV, where transmission intensity is driven by complex interactions between vector abundance, climate, and host immunity. More recently, the southcentral Appalachian region has been identified as an area of concern, with ongoing studies investigating seroprevalence in sheep populations where anecdotal reports suggest CVV circulation [24]. The isolation of CVV from an aborted lamb in Arkansas in 2023 and the subsequent One Health investigation highlights the expanding footprint of this pathogen and the need for increased veterinary surveillance [22, 19]. The virus's capacity to cause devastating reproductive losses in sheep and goats, coupled with its wide distribution and the expanding range of competent mosquito vectors such as Aedes albopictus, positions CVV as a growing threat to small ruminant production systems across the continent [12, 15].

Human Clinical Manifestations and Zoonotic Potential

The Emerging Spectrum of Human Disease

Cache Valley virus (CVV) has historically been regarded as a veterinary pathogen of consequence primarily for ruminant livestock; however, a growing body of evidence over the past two decades has unequivocally established its capacity to cause severe, and occasionally fatal, disease in humans [1, 2]. The human clinical spectrum of CVV infection remains poorly characterized due to the extreme rarity of diagnosed cases, a phenomenon almost certainly attributable to profound under-ascertainment and diagnostic neglect rather than true clinical insignificance [1, 25]. As of the most comprehensive reviews, fewer than a dozen laboratory-confirmed human infections have been documented in the peer-reviewed literature, a number that stands in stark contrast to seroprevalence studies demonstrating widespread prior exposure in human populations across the Americas [1, 2, 25]. This discrepancy signals a critical gap in our understanding: the vast majority of CVV infections in humans are likely asymptomatic, subclinical, or associated with a mild, non-specific febrile illness that is never etiologically diagnosed [10, 2].

The first recognized human cases were characterized by acute neuroinvasive disease, establishing early in the virus's history as a human pathogen that CVV possesses a potent neurotropic capacity [25]. The initial documented human infection, reported from the United States, presented with meningoencephalitis, a finding that shaped the early perception of CVV as a primarily neurological threat in humans [2, 25]. This phenotype was subsequently reinforced by the second reported human case, which similarly involved severe central nervous system (CNS) involvement [25]. However, the clinical paradigm has since expanded to include a wider and more nuanced spectrum of illness, ranging from acute febrile, non-neurologic syndromes to chronic, progressive meningoencephalitis in immunocompromised hosts [10, 29].

Detailed clinical characterization of the non-neurologic presentation has been provided by the description of a reassortant CVV strain isolated from an adult male in Missouri [10]. This patient initially presented with a constellation of symptoms including fever, profound fatigue, and gastrointestinal distress, accompanied by laboratory findings of leukopenia and thrombocytopenia, a clinical picture initially suspicious for a tickborne illness such as ehrlichiosis or anaplasmosis [10]. The patient's condition deteriorated markedly, progressing to respiratory failure, renal failure, lactic acidosis, and hypotension, demonstrating that CVV can induce a severe, multi-system inflammatory syndrome reminiscent of viral hemorrhagic fever or septic shock, even in the absence of overt neurological signs [10]. This case is particularly instructive as it underscores the potential for clinical misdiagnosis; the non-specific, flu-like prodrome of CVV infection is easily conflated with more common arboviral or bacterial etiologies, particularly in regions where tickborne diseases are endemic [10, 2].

The neuroinvasive manifestations of CVV, however, remain the most clinically consequential and best-documented phenotype. These cases typically present with acute or subacute onset of meningoencephalitis, with cerebrospinal fluid (CSF) analysis revealing a lymphocytic pleocytosis, elevated protein, and normal glucose, a profile consistent with viral encephalitis [27, 25]. Clinically, patients exhibit altered mental status, cognitive impairment, confusion, and focal neurological deficits [27]. Magnetic resonance imaging (MRI) findings in neuroinvasive CVV disease have been reported as variable, ranging from normal to showing non-specific diffuse dural enhancement, without the characteristic focal parenchymal lesions seen in some other arboviral encephalitides [27]. This lack of pathognomonic imaging features further complicates diagnosis, as clinicians must rely on a high index of suspicion and specialized laboratory testing [27, 28].

The Critical Role of Immune Status

Perhaps the most salient theme emerging from the literature is the profound impact of host immune status on the clinical trajectory and severity of human CVV infection. The virus appears to be exquisitely opportunistic, with the most severe and unusual presentations occurring almost exclusively in individuals with compromised immune systems [26, 30, 29, 27]. This pattern is strikingly illustrated by a series of cases involving patients receiving immunosuppressive therapies or those with primary immunodeficiencies.

A landmark case was reported in a 58-year-old man from rural New York with a history of chronic lymphocytic leukemia (CLL) who was receiving maintenance therapy with rituximab, a B-cell-depleting monoclonal antibody [27]. This patient presented with a one-month history of progressive confusion, irritability, memory loss, gait instability, and fatigue, without fever [27]. His neurological examination revealed cognitive dysfunction, brisk reflexes, ankle clonus, and a wide-based gait [27]. CSF analysis showed a T-cell-predominant pleocytosis and markedly elevated protein [27]. Despite an exhaustive workup for common infectious, paraneoplastic, and autoimmune etiologies, the diagnosis was only established after extensive testing, identifying CVV as the causative agent [27]. This case highlights several critical points: first, the insidious, subacute-to-chronic course of CVV neuroinvasive disease in the setting of B-cell deficiency, where the humoral immune response is critically impaired by rituximab therapy; second, the diagnostic odyssey that such patients endure when rare pathogens are not considered; and third, the ability of CVV to cause a chronic, progressive encephalitis in the absence of classic acute febrile prodrome [27].

The vulnerability of the immunocompromised host is further underscored by a case of transfusion-transmitted CVV infection in a kidney transplant recipient, which resulted in severe meningoencephalitis [26]. This individual, heavily immunosuppressed to prevent graft rejection, developed encephalitis six weeks post-transplantation following receipt of multiple blood transfusions [26]. Metagenomic next-generation sequencing (mNGS) of CSF, a powerful diagnostic tool for identifying unexpected pathogens, revealed CVV, and a subsequent traceback investigation identified the source as an infected blood donor [26]. This case is of profound public health significance for several reasons: it provides the first documented evidence of parenteral CVV transmission via blood transfusion, it demonstrates the utility of advanced molecular diagnostics in complex clinical scenarios, and it raises critical questions about the screening of blood products for emerging arboviruses [26]. The index patient’s profound immunosuppression likely enabled the establishment of a high-level viremia and subsequent neuroinvasion from a transfusion-acquired infection, a scenario that might have been clinically silent or self-limited in an immunocompetent individual [26].

The spectrum of vulnerability extends to individuals with primary immunodeficiencies, as demonstrated by the first reported pediatric case of CVV encephalitis, which occurred in an adolescent with an IKZF1/Ikaros immunodeficiency [30]. This case further reinforces the centrality of intact immune function, particularly the type I interferon pathway and humoral immunity, in controlling CVV replication and preventing CNS invasion [30, 31]. Experimental murine models have provided mechanistic corroboration for these clinical observations, demonstrating that mice deficient in the type I interferon receptor (IFN-αβR-/-) are exquisitely susceptible to lethal CVV infection, whereas immunocompetent adult mice are largely resistant to disease [31]. These data establish that the type I interferon response is the primary innate immune barrier against CVV dissemination, and that its impairment, whether genetic or iatrogenic, is a major risk factor for severe human disease [31].

Zoonotic Potential and Transmission Dynamics

The zoonotic potential of CVV is unequivocal, as evidenced by human infections acquired through natural mosquito-borne transmission in endemic areas [10, 2, 27, 25]. CVV is maintained in an enzootic cycle primarily involving various mosquito species and wild mammalian hosts, with white-tailed deer (Odocoileus virginianus) identified as a critical amplifying host [11, 8, 15]. Human infection occurs when infected bridge vectors, such as Culex tarsalis and Aedes albopictus, feed on humans, representing spillover from this sylvatic cycle [12, 14, 13]. The identification of CVV in Aedes albopictus, a highly anthropophilic and invasive mosquito species that thrives in peridomestic environments, is particularly concerning as it suggests a mechanism for efficient urban and suburban transmission to humans [9, 12]. Experimental vector competence studies have confirmed that Ae. albopictus is a highly competent vector for CVV, with transmission rates as high as 62% under laboratory conditions, while Ae. aegypti appears less susceptible [12, 13]. This differential competence has significant epidemiological implications, as the expanding geographic range of Ae. albopictus across North America and the New World may be facilitating increased human exposure to CVV [11, 12].

The documented risk of transfusion-transmitted CVV further elevates the zoonotic and public health concern associated with this pathogen [26]. Unlike arthropod-borne transmission, which relies on a competent vector, contaminated blood products can directly introduce the virus into the human bloodstream, bypassing cutaneous barriers and potentially leading to higher inocula and more severe disease, particularly in immunocompromised recipients [26]. This finding necessitates a reevaluation of blood safety protocols, particularly during periods of high arbovirus transmission activity, and highlights the need for sensitive screening assays for CVV in blood donor populations [26].

The full geographic extent of human CVV risk is only beginning to be appreciated. Ecological niche modeling suggests that large areas of North America, including regions with no documented human cases, possess suitable climatic, vector, and host conditions for CVV transmission [11]. Seroprevalence surveys have detected neutralizing antibodies in human populations across Latin America and the United States, indicating that infection is far more common than diagnosed cases suggest [1, 2, 35]. A particularly striking finding from a study in Yucatán, Mexico, using a newly developed IgM antibody capture ELISA, identified recent CVV infections among febrile patients who had tested negative for other common arboviruses [35]. This suggests that CVV is a previously unrecognized cause of acute febrile illness in tropical and subtropical regions of the Americas, where diagnostic testing for CVV is rarely performed [35].

A Critical Knowledge Gap: The Potential for Human Teratogenicity

Perhaps the most pressing and unanswered question regarding the zoonotic potential of CVV is its capacity to cause congenital malformations in humans, analogous to its well-documented teratogenic effects in ruminants [1, 2, 34]. In sheep and goats, CVV infection during the first trimester of pregnancy consistently results in a devastating spectrum of fetal outcomes, including embryonic death, resorption, mummification, and severe central nervous system and musculoskeletal malformations such as arthrogryposis, hydranencephaly, kyphosis, and scoliosis [18, 19, 20, 21, 16]. The virus has a remarkable tropism for rapidly dividing fetal neural tissues, and the timing of infection is exquisitely critical, with the most severe defects occurring when dams are infected between 27 and 50 days of gestation, a period corresponding to neural tube closure and early organogenesis [16, 17].

This clear demonstration of teratogenicity in a mammalian species raises the biologically plausible concern that CVV could similarly cause human birth defects [1, 34]. A direct investigation into this question was conducted following a 1990-1991 outbreak of neural tube defects (NTDs), including anencephaly, in south Texas, a region with known CVV activity in livestock [34]. The study tested serum from women who had given birth to infants with NTDs for CVV neutralizing antibodies, hypothesizing that recent or past infection might be associated with the defects [34]. The results were negative; none of the women tested had detectable CVV antibodies [34]. While this study provided some reassurance, it was limited by its small sample size, its reliance on neutralizing antibodies (which may wane over time), and its focus on a non-epidemic period [34]. The authors themselves cautioned that their findings do not preclude the possibility of CVV-induced human teratogenicity during an epidemic, or the involvement of other, closely related orthobunyaviruses [34].

The lack of any systematic surveillance for CVV infection during pregnancy, and the absence of a large-scale epidemiological study linking maternal CVV seroconversion to adverse pregnancy outcomes, means that the question of human teratogenicity remains entirely unresolved [1]. The development of a murine model for in utero CVV transmission has provided a critical tool to begin addressing this question experimentally. These studies have demonstrated that CVV can efficiently cross the murine placenta, causing high rates of spontaneous abortion and congenital malformations in immunocompromised mouse models, further validating the biological plausibility of human transplacental transmission [31]. The development of a robust and accessible serological diagnostic, such as the MAC-ELISA, will be essential for conducting the prospective cohort studies needed to definitively assess the risk to pregnant women [35]. Until such studies are performed, the potential for CVV to act as a human teratogen remains a grave and unresolved public health concern.

Diagnostic Challenges in the Human Host

The accurate diagnosis of human CVV infection is fraught with challenges, which directly contributes to the profound underreporting of cases [1, 4, 35]. The current gold standard serological test, the plaque reduction neutralization test (PRNT), requires live CVV, is time-consuming (several days), must be performed in a biosafety level 2 (BSL-2) containment facility, and cannot distinguish between recent and past infections [4, 35]. This makes it unsuitable for routine clinical diagnostic use and limits its availability to specialized reference laboratories [35]. The recent development of an IgM antibody capture ELISA (MAC-ELISA) represents a significant advance, offering a faster, less resource-intensive method that can detect recent infection by targeting the IgM antibody response [35]. This assay has shown good initial specificity, with no cross-reactivity observed in sera from patients with other arboviral infections [35]. However, cross-reactivity with other orthobunyaviruses, such as Tensaw, Fort Sherman, and Potosi viruses, remains a concern for serological assays based on the nucleoprotein, and confirmation with PRNT may still be required for definitive diagnosis [4, 35].

Molecular detection via reverse transcription-polymerase chain reaction (RT-PCR) offers the potential for earlier, definitive diagnosis by detecting viral RNA in CSF, serum, or tissue [26, 37]. A duplex real-time RT-PCR assay has been developed for CVV and California serogroup viruses, demonstrating high sensitivity and specificity [37]. However, the window for detecting CVV RNA in human clinical samples is likely narrow, as the viremic phase is probably short-lived, making RT-PCR less useful in patients presenting with late-onset neuroinvasive disease [26]. In such cases, metagenomic next-generation sequencing (mNGS) of CSF has proven to be a powerful, albeit expensive and not widely available, diagnostic tool, capable of detecting CVV even when conventional assays fail [26, 10, 29]. The increasing use of mNGS for undiagnosed meningoencephalitis is likely to uncover additional cases of CVV infection and expand the known clinical spectrum of the disease [29]. The diagnostic gap is compounded by a general lack of clinical awareness; most physicians have never heard of CVV and do not consider it in their differential diagnosis for patients presenting with febrile illness or encephalitis [2, 28]. This diagnostic challenge is the single greatest barrier to understanding the true human disease burden of Cache Valley virus.

Diagnostic Techniques for Cache Valley Virus

The accurate and timely diagnosis of Cache Valley virus (CVV) infection presents a formidable challenge, reflecting the virus’s position as an understudied yet emerging arboviral pathogen of significant public health and agricultural consequence [1, 2]. The diagnostic landscape for CVV is characterized by a critical tension: the need for high-specificity assays to differentiate it from a vast array of antigenically related orthobunyaviruses, versus the need for rapid, high-throughput, and accessible tests suitable for surveillance and outbreak response. Historically, the diagnostic armamentarium has been limited, relying heavily on the plaque reduction neutralization test (PRNT) – a gold standard that is laborious, time-consuming, requires live virus and high-level biocontainment (BSL-3), and cannot distinguish between recent and past infections [1, 4, 35]. The resultant diagnostic bottleneck has almost certainly contributed to the profound underreporting of CVV in both human and veterinary populations [2, 25]. However, recent years have witnessed a concerted effort to expand and refine diagnostic capabilities, driven by the recognition of CVV’s teratogenicity in ruminants and its potential to cause severe neuroinvasive disease in immunocompromised humans. This section provides an exhaustive examination of the current and emerging diagnostic techniques for CVV, critically analyzing their mechanisms, applications, limitations, and the pressing gaps that remain.

Serological Diagnostics: The Cornerstone and Its Evolution

The Plaque Reduction Neutralization Test (PRNT)

PRNT remains the unequivocal gold standard for CVV serodiagnosis, serving as the definitive arbiter of specificity due to its ability to detect functional neutralizing antibodies [1, 18, 6, 23]. The assay’s principle hinges on the incubation of serial dilutions of patient or animal serum with a standardized, quantified dose of live CVV. Following incubation, the serum-virus mixture is applied to a monolayer of susceptible cells (typically Vero or BHK-21 cells), and a semi-solid overlay is added to prevent secondary foci of infection. After a defined incubation period (typically 3-5 days), plaques, zones of cytopathic effect representing individual infectious foci, are enumerated. A reduction in plaque count relative to a virus-only control is interpreted as evidence of neutralizing activity in the serum. A titer is defined as the reciprocal of the highest serum dilution that reduces the number of plaques by a specified percentage, commonly 50% (PRNT₅₀) or 90% (PRNT₉₀) [19, 33]. For CVV, a PRNT₅₀ titer ≥ 10 has been used as a conservative threshold for seropositivity in ruminants [19, 6, 23].

The unparalleled specificity of PRNT is its paramount advantage. It is the only serological assay that can reliably discriminate between infection with CVV and other closely related orthobunyaviruses, such as Tensaw, Fort Sherman, Maguari, and Potosi viruses, which exhibit significant antigenic cross-reactivity in binding-based immunoassays [4, 2]. This specificity has made PRNT indispensable for confirmatory testing in human case investigations [26, 25, 16] and for epidemiological seroprevalence studies in sheep [18, 23, 24]. The World Organisation for Animal Health (WOAH) and the U.S. Centers for Disease Control and Prevention (CDC) consider PRNT the reference standard for arboviral diagnostics. However, the technique is fraught with practical limitations. It is extremely labor-intensive, requiring meticulous pipetting and cell culture expertise. The turnaround time is protracted, typically taking 5-7 days to obtain results. Furthermore, the requirement for live, replication-competent CVV restricts performance to BSL-3 facilities, a barrier for most state, provincial, and veterinary diagnostic laboratories [1, 4, 35]. Critically, PRNT cannot differentiate between IgM and IgG antibodies, meaning a single positive titer can only indicate past exposure and cannot reliably distinguish recent infection from an anamnestic response, a crucial distinction for determining the timing of infection during pregnancy [1, 35].

The Immunoglobulin M Antibody Capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA)

To overcome the limitations of PRNT, particularly regarding speed and the discrimination of recent infection, a novel MAC-ELISA for the detection of anti-CVV human IgM antibodies has recently been developed [35]. This represents a monumental step forward in CVV diagnostics. The MAC-ELISA is a rapid immunoassay that can be performed in as little as 2-3 hours and does not require live virus, making it deployable in BSL-2 laboratories.

The technical foundation of this assay is elegantly constructed. Microtiter plates are coated with anti-human IgM antibodies, which capture total IgM from the patient serum sample, irrespective of antigen specificity. A recombinant, biotinylated CVV antigen (specifically the nucleoprotein, N) is then added. The captured CVV-specific IgM binds this antigen. The bound antigen is then detected using a streptavidin-horseradish peroxidase conjugate and a chromogenic substrate, producing a measurable signal [35]. The development of this assay was contingent upon the generation of a continuous source of high-quality, standardized positive control material. This was achieved through the construction of a novel cell line constitutively expressing a human-murine chimeric monoclonal antibody (cMAb) with the variable regions of the anti-CVV MAb CVV-17 and the constant regions of human IgM. This cMAb provides an inexhaustible and reproducible positive control, circumventing the severe limitations of relying on limited and variable convalescent human sera [4, 35].

Performance characteristics of this CVV MAC-ELISA are promising. In a foundational validation study, the assay correctly identified five of seven archived human specimens from confirmed CVV cases, demonstrating a sensitivity of 71.4% [35]. In the same study, 44 specimens from patients with confirmed infections by other arboviruses (e.g., West Nile, dengue, chikungunya) were uniformly negative (100% specificity), indicating no cross-reactivity with these major human pathogens [35]. The assay also proved its investigative utility by identifying two possible recent CVV infections among 27 febrile patients from Yucatán, Mexico, whose sera were negative for flavivirus and alphavirus antibodies but positive in both the MAC-ELISA and PRNT [35]. This highlights the potential of the MAC-ELISA as a frontline screening tool in fever of unknown origin surveillance. While this assay was developed for human diagnostics, its principle could be adapted for veterinary species, though species-specific anti-IgM conjugates would be required.

Monoclonal Antibodies (MAbs) and Antigen Detection

The development of a panel of murine monoclonal antibodies directed against the CVV nucleoprotein has further enriched the diagnostic toolkit [4]. Twelve hybridoma clones secreting anti-CVV MAbs were generated, all of which were non-neutralizing and specific to the N protein. This panel is crucial for developing and standardizing various immunoassays. Of particular note, MAbs CVV-14, CVV-15, CVV-17, and CVV-18 were identified as having high specific reactivity and were successfully employed as detector antibodies in the MAC-ELISA format, with CVV-17 being the basis for the chimeric control [4]. These MAbs can also be used to develop direct antigen-capture ELISAs, immunohistochemistry protocols for detecting viral antigen in formalin-fixed, paraffin-embedded fetal tissues, and lateral flow devices for rapid point-of-care testing. However, a critical caveat to their use is the observed cross-reactivity. Several of the MAbs reacted with other related orthobunyaviruses, including Tensaw, Fort Sherman, and Maguari viruses [4]. This cross-reactivity limits the utility of these MAbs for serotyping or for definitive diagnosis in regions where multiple orthobunyaviruses co-circulate, reinforcing the need for PRNT confirmation of any binding-based immunoassay result.

Molecular Diagnostics: Direct Detection of Viral RNA

Molecular techniques, primarily reverse transcription-polymerase chain reaction (RT-PCR), offer the distinct advantage of detecting active viral infection by directly amplifying viral RNA, rather than relying on the host’s antibody response. This is paramount for early diagnosis during the acute viremic phase in humans and for confirming infection in aborted fetal tissues, where maternal antibodies may not yet be present or may be passively transferred.

Conventional and Duplex Real-Time RT-PCR Assays

A landmark advancement was the development of a duplex TaqMan real-time RT-PCR assay designed for the simultaneous detection and differentiation of California (CAL) serogroup viruses and CVV [37]. This assay was purpose-built for human surveillance and vector screening. The strategy involves two distinct targets: the nucleocapsid protein (N) gene for the conserved CAL serogroup, and the glycoprotein G1 (Gn) gene for specific detection of CVV. By aligning sequences from diverse CVV strains, conserved regions within the Gn gene were identified to ensure broad reactivity [37]. The analytical sensitivity is exceptional, with a limit of detection of 30 gene copies per reaction for CVV [37]. The assay demonstrated remarkable linearity over a 6-log₁₀ dynamic range and showed no cross-reactivity with a panel of other viral and bacterial pathogens. Crucially, it successfully detected 12 different CVV isolates, demonstrating its robustness against genetic diversity [37]. The inclusion of an internal control (e.g., an exogenous RNA template or a host gene such as β-actin) is a standard and essential feature, as it monitors for nucleic acid extraction efficiency and the presence of RT-PCR inhibitors, which is particularly important for complex sample matrices like fetal tissues or mosquito pools [37].

This assay has been validated for use on a wide range of clinical specimens. In a pivotal One Health investigation of an aborted lamb in Arkansas, a bunyavirus-specific RT-PCR, followed by CVV-specific RT-PCR, was instrumental in confirming the presence of CVV RNA in kidney tissues [22, 19]. The ability to detect CVV RNA not only confirms infection but also provides a template for downstream applications such as sequencing and phylogenetic analysis, which are critical for tracking viral evolution, reassortment events, and lineage displacement [8, 10]. For example, metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) has been used to identify a rare reassortant CVV strain in a human case of acute febrile illness with multi-organ failure, a feat impossible by standard PCR [10]. Similarly, mNGS identified CVV as the causative agent in a case of transfusion-transmitted meningoencephalitis in a kidney transplant recipient [26] and in a pediatric case of chronic meningoencephalitis in an immunocompromised child [30, 29].

Metagenomic Next-Generation Sequencing (mNGS)

mNGS represents the apex of unbiased pathogen discovery. Unlike targeted PCR, mNGS sequences all nucleic acids present in a clinical sample, allowing for the detection of any pathogen, including novel, divergent, or unexpected agents, without prior knowledge or specific primers. For CVV, mNGS has been a transformative tool in diagnosing neuroinvasive disease in immunocompromised patients, where conventional testing is frequently unrevealing [26, 10, 29, 27]. In the index case of transfusion-transmitted CVV, mNGS of CSF provided the first clue of infection, which was then confirmed by RT-PCR, culture, and whole-genome sequencing [26]. The utility of mNGS is particularly high in cases of chronic meningoencephalitis, where viral loads may be low and the differential diagnosis is broad [29]. Despite its power, mNGS remains expensive, requires specialized bioinformatics expertise, and has a turnaround time of several days to weeks, making it unsuitable for acute clinical decision-making but invaluable for public health investigations and identifying new emerging strains or reassortants [10].

Virus Isolation and Characterization

The gold standard for confirming an active, replicating infection is the isolation of infectious virus from clinical specimens. Historically, CVV has been isolated from a wide range of sources, including mosquitoes [8, 15, 14], the blood of a clinically normal horse [33], and from aborted fetal tissues and allantoic fluid of experimentally infected sheep [16]. Isolation is typically performed by inoculating susceptible cell lines, most commonly Vero (African green monkey kidney) or BHK-21 (baby hamster kidney) cells, with homogenized tissue or body fluid [8, 16, 5]. The presence of virus is detected by the appearance of characteristic cytopathic effect (CPE), which is then confirmed by immunofluorescence using the specific MAbs or by RT-PCR. While virus isolation is definitive and provides a live viral stock for further characterization (e.g., plaque size, growth kinetics, whole-genome sequencing, vector competence studies), it is slow (days to weeks), requires BSL-3 containment, and is insensitive if the sample is not collected during the brief viremic period or if the virus has been inactivated by autolysis or freeze-thaw cycles [2].

Diagnostic Approaches in Specific Contexts

Diagnosis in Ruminants with Suspect Congenital Malformations

Diagnosis of CVV as a cause of fetal loss and congenital malformations (arthrogryposis, hydranencephaly, cerebellar hypoplasia) is based on a combination of clinical, serological, and molecular methods in the dam and the fetus [18, 20, 21, 16, 17]. In the dam, seroconversion, as demonstrated by a significant rise in PRNT titer between acute and convalescent sera, or the presence of a high titer in a single sample taken after abortion, is strongly supportive of recent infection. However, maternal serology alone is insufficient to confirm infection in the fetus. Definitive diagnosis requires testing of the fetus or fetal tissues. The World Organisation for Animal Health (WOAH) recommends a multi-pronged approach:

1. RT-PCR on fetal tissues: Brain, spinal cord, liver, spleen, and kidney are the samples of choice for viral RNA detection [22, 19, 16].
2. Virus isolation: From the same tissues, particularly if they are fresh and collected promptly.
3. Immunohistochemistry (IHC): Using anti-CVV N protein MAbs on formalin-fixed, paraffin-embedded fetal brain tissue to detect viral antigen in situ, providing a direct link between pathology and infection.
4. Fetal serology (PRNT): The presence of CVV-specific neutralizing antibodies in fetal serum or pericardial fluid is diagnostic of in utero infection, as the fetus becomes immunocompetent around 60-70 days of gestation [16]. Absence of antibody does not rule out infection, particularly in fetuses infected early in gestation (<50 days), which may be seronegative [21, 16].

Diagnosis in Humans with Suspect Neuroinvasive Disease

For human cases, the diagnostic approach follows the CDC’s established arboviral testing algorithm. Acute serum and CSF samples are the specimens of choice.

1. RT-PCR and mNGS on CSF: For immunocompromised patients or those presenting early in illness, RT-PCR or mNGS on CSF offers the highest chance of direct pathogen detection [26, 30, 29, 27].
2. Serology (MAC-ELISA and PRNT): The new CVV MAC-ELISA is the recommended first-line serological test for detecting recent infection in serum and potentially CSF [35]. A positive result should be confirmed by PRNT to ensure specificity against other orthobunyaviruses. A four-fold rise in PRNT titer between acute and convalescent sera is considered confirmatory of recent infection.
3. Rule out other arboviruses: Due to overlapping clinical presentations and geographical risk, testing for West Nile, St. Louis encephalitis, Eastern Equine Encephalitis, and other arboviruses is mandatory in any encephalitis workup [28].

Challenges and Future Directions

Despite these advances, major diagnostic gaps persist. The critical issue of serological cross-reactivity within the Orthobunyavirus genus remains unresolved. Antibodies against CVV can cross-react with Tensaw, Potosi, and other viruses, and conversely, infection with these viruses may produce a false-positive

Current Knowledge Gaps and Future Research Directions

Despite over six decades having passed since the initial isolation of Cache Valley virus (CVV) from Culiseta inornata in Utah, the scientific understanding of this orthobunyavirus remains profoundly fragmented and disproportionately sparse relative to its demonstrated capacity for both epizootic devastation and zoonotic neuroinvasion [1, 2]. The virus occupies a peculiar and troubling niche: it is simultaneously recognized as a significant agricultural pathogen, capable of inducing catastrophic congenital malformations in ruminant populations, and an emerging human pathogen with the potential for severe, even fatal, neurological disease, particularly in immunocompromised individuals [1, 29, 27]. Yet, the very attributes that elevate its threat profile, its wide geographic distribution, its utilization of multiple vector species, and its documented ability to reassort, are also the most poorly characterized. The current body of knowledge, as synthesized from the available literature, reveals a landscape riddled with critical lacunae that impede the development of effective surveillance, diagnostic, therapeutic, and preventive strategies. A concerted, multi-disciplinary research program, grounded in the principles of One Health, is not merely advisable but urgently necessary to preempt a potential public health and agricultural crisis.

Diagnostic and Surveillance Deficiencies: The Invisible Arbovirus

A foundational obstacle to understanding CVV’s true burden is the profound inadequacy of current diagnostic and surveillance infrastructure. The plaque reduction neutralization test (PRNT), long considered the gold standard, is a technically demanding, time-consuming, and labor-intensive assay that requires live virus and high-level biocontainment (BSL-3) facilities, rendering it unsuitable for high-throughput screening or deployment in most diagnostic laboratories [1, 4]. While the recent development of an IgM antibody capture ELISA (MAC-ELISA) represents a significant step forward, enabling faster detection of recent infections, its validation has been limited to a small number of archived human specimens [35]. The MAC-ELISA’s sensitivity, specificity, and cross-reactivity profile against a broader panel of related orthobunyaviruses (e.g., Tensaw, Potosi, Maguari) across diverse geographic regions and in different animal species remain largely unassessed [4]. A critical gap is the absence of a validated, commercially available, high-throughput serological assay suitable for large-scale serosurveys in both human and livestock populations. Without such tools, the true seroprevalence of CVV, and consequently, the true incidence of infection and disease, will remain speculative. Public health authorities, including the CDC, have acknowledged this diagnostic gap, but coordinated efforts to bridge it are nascent.

Furthermore, the reliance on passive surveillance for human cases is demonstrably flawed. The handful of reported human cases, often identified only through fortuitous application of metagenomic next-generation sequencing (mNGS) in complex clinical scenarios [26, 10, 29], almost certainly represents a dramatic underestimate of the true disease burden. CVV disease likely masquerades as undifferentiated febrile illness or aseptic meningitis, conditions for which etiological workups are rarely, if ever, performed [10, 25, 28]. The essential question of whether CVV acts as a human teratogen remains completely unanswered, representing perhaps the single most alarming gap in the literature [1, 34]. The only study to directly address this hypothesis, a serosurvey of women whose infants had neural tube defects in Texas, was limited in scope and temporal specificity, and its negative result cannot be considered definitive [34]. Future research must prioritize large-scale, prospective cohort studies in regions with known CVV enzootic activity that rigorously investigate the association between maternal CVV infection (confirmed by seroconversion or RT-PCR) and adverse pregnancy outcomes, including congenital anomalies, spontaneous abortion, and stillbirth. This effort should be extended to include serosurveys of cord blood and surveillance of fetal tissues for CVV RNA.

The Unresolved Ecology of Transmission and Amplification

The sylvatic transmission cycle of CVV is portrayed in broad, unsatisfactory strokes. Ecological niche modeling suggests a continental-level potential distribution across North America, identifying Aedes vexans, Culiseta inornata, and Culex tarsalis as likely primary vectors and white-tailed deer (Odocoileus virginianus) as a probable key amplifying host [11]. However, these models are correlative, not causal. They identify suitable environmental niches but do not elucidate the mechanistic determinants of transmission intensity, the relative contribution of different host species to viral amplification, or the ecological triggers that precipitate spillover into livestock and humans. The recent discovery of CVV in Aedes albopictus, an aggressive, anthropophilic, and globally invasive species, has profound implications for urban and peri-urban transmission [9, 12]. Laboratory vector competence studies for Ae. albopictus show high transmission potential [12, 13], but the extent to which this species drives human exposure in nature is unknown. Similarly, the role of Aedes japonicus japonicus, another invasive species expanding its range, in the Appalachian region warrants further investigation [15]. The surprising detection of CVV in Anopheles mosquitoes and evidence suggesting their role in lineage displacement in New York State [8] compels a fundamental reassessment of the canonical vector associations. Future research must move beyond static competence experiments and ecological correlations to dynamic field studies that quantify vector-host contact rates, estimate the vectorial capacity of different mosquito species in real-world scenarios, and identify the landscape-level factors that govern spillover risk. This necessitates longitudinal, multi-site surveillance programs that integrate mosquito trapping, host serosurveys, and viral sequencing to map transmission networks in space and time. The potential for non-vectorborne transmission, dramatically demonstrated by a single case of transfusion-transmitted CVV leading to fatal meningoencephalitis in a kidney transplant recipient [26], also demands rigorous investigation to define the risk to the blood supply, especially in immunocompromised patient populations.

Viral Pathogenesis and the Molecular Basis of Disease

At the molecular level, the mechanisms by which CVV causes its hallmark pathologies, teratogenesis in ruminants and neuroinvasion in humans, are poorly understood. The development of a murine model, particularly using IFN-αβR-/- mice, has provided a critical tool for studying pathogenesis and has confirmed the central role of the type I interferon response in restricting CVV replication [31]. This model also successfully recapitulated in utero transmission and congenital malformations, opening avenues for mechanistic studies of teratogenesis [31]. However, extrapolating from an immunocompromised mouse to a pregnant ewe or a human patient requires a substantial leap. The specific viral determinants that govern tissue tropism, why does the virus preferentially infect the developing fetal central nervous system in ruminants, and why does it target the brain in immunocompromised humans?, are unknown. The nonstructural proteins NSs and NSm are clear virulence factors; NSs functions as an interferon antagonist, and their deletion results in a profoundly attenuated phenotype [6, 7, 5]. However, the precise molecular interactions between these viral proteins and host cellular machinery remain to be fully elucidated. Furthermore, the phenomenon of reassortment, a hallmark of segmented viruses, has been documented for CVV [8, 10] and poses a significant threat. Reassortment between circulating strains, or even between CVV and related orthobunyaviruses like Kairi virus, could generate novel genotypes with altered virulence, host range, or vector competence [5]. The failure to recover M segment reassortants between CVV and KRIV in a laboratory setting [5] is reassuring but does not preclude the occurrence of such events in nature, particularly under high co-infection pressure. Systematic surveillance programs that include full-genome sequencing of CVV isolates from diverse sources (mosquitoes, wildlife, livestock, humans) are essential to detect emergent reassortants and predict shifts in viral phenotype. A deeper understanding of viral structure, including the atomic resolution of the glycoprotein complex and its interaction with host cell receptors, is also a critical prerequisite for rational drug design.

Antiviral and Vaccine Development: A Preclinical Pipeline Vacuum

The development of countermeasures for CVV is in its infancy, and the pipeline is perilously thin. The demonstration that a live-attenuated vaccine (LAV) with deletions in NSs and NSm (2delCVV) is immunogenic in sheep and safe in mosquitoes (showing poor replication) is promising and represents the most advanced vaccine candidate [6, 7]. However, this LAV is far from ready for field deployment. Comprehensive safety studies, including the assessment of reversion to virulence, the potential for reassortment with wild-type viruses, and the duration of protective immunity, are needed. The inactivated vaccine (BEI-CVV) provides a less immunogenic but potentially safer alternative [6]; comparative efficacy trials in pregnant ewes against wild-type CVV challenge are the necessary next step to establish a correlate of protection. For human use, the regulatory and safety hurdles are far higher, and no candidate human vaccine is currently on the horizon.

The antiviral landscape is even more barren. The identification of 11 small molecules from a high-throughput screen that inhibit CVV replication, including three that appear to target the viral RNA-dependent RNA polymerase (RdRp) [3], offers a glimmer of hope. One of these compounds has shown broad-spectrum activity against other bunyaviruses, including Rift Valley fever virus and Andes virus [3]. Most notably, a single case report documented clearance of CVV from the cerebrospinal fluid of an immunocompromised child with meningoencephalitis following treatment with molnupiravir, a nucleoside analog [30]. These are tantalizing but preliminary findings. Rigorous preclinical evaluation of these candidates in the established murine model [31] is essential to determine their pharmacokinetics, efficacy, and toxicity, particularly in the context of pregnancy and neuroinvasion. The development of a robust, rationally designed antiviral pipeline, targeting conserved viral functions like the RdRp or the glycoprotein, is a critical priority for the global health security agenda.

One Health Integration and Socioeconomic Impact Quantification

Perhaps the most critical overarching gap is the lack of a truly integrated One Health approach. While investigations such as the Arkansas response [22] exemplify the collaborative spirit needed, they remain ad hoc and reactive. The World Organisation for Animal Health (WOAH) currently lists CVV as a notifiable disease in ruminants, but reporting is inconsistent and likely underrepresents the true epizootic footprint. There is no coordinated, multi-national surveillance system that simultaneously monitors viral activity in mosquitoes, wildlife, livestock, and humans. The true economic burden of CVV on the agricultural sector, from direct losses due to abortion, congenital defects, and dystocia, to indirect costs of management interventions and lost productivity of breeding stock, has not been systematically quantified. Preliminary data suggest CVV can reduce the number of live lambs born by 18% and those weaned by 27% [19], figures that, if extrapolated across the North American sheep industry, represent a substantial but unmeasured economic drain. Similarly, the human health burden, including the cost of diagnostic workups for undifferentiated encephalitis, the morbidity of severe neurological sequelae, and the potential, unconfirmed teratogenic risk, remains an economic unknown.

Future research must be structured around a coherent One Health framework that explicitly links these domains. This includes: (1) establishing sentinel surveillance in sheep flocks as an early warning system for human risk, given their shared mosquito exposure; (2) conducting economic analyses to quantify the full cost of CVV to both the livestock industry and the healthcare system; (3) investigating the role of climate change in altering the geographic range and seasonal transmission dynamics of CVV, a topic that has been completely ignored in the literature [2]; and (4) developing decision-support tools for veterinarians and public health officials that integrate real-time surveillance data with predictive risk models. Without a coordinated, adequately funded, interdisciplinary research agenda that addresses these fundamental gaps, Cache Valley virus will remain a "neglected" arbovirus of potentially immense consequence, poised to cause escalating disease and economic loss in both animal and human populations across the Americas.

References

[1] Hughes HR, Kenney JL, Calvert AE. Cache Valley virus: an emerging arbovirus of public and veterinary health importance. Journal of medical entomology. 2023. DOI: https://doi.org/10.1093/jme/tjad058

[2] Waddell L, Pachal N, Mascarenhas M, Greig J, Harding S, Young I, et al.. Cache Valley virus: A scoping review of the global evidence. Zoonoses and Public Health. 2019. DOI: https://doi.org/10.1111/zph.12621

[3] Khalid M. Identification of small molecule inhibitors targeting Cache Valley virus replication and establishment of reverse genetics for swine mammalian orthoreovirus. . None. DOI: https://doi.org/10.32469/10355/110357

[4] Skinner B, Mikula S, Davis B, Powers JA, Hughes HR, Calvert AE. Monoclonal antibodies to Cache Valley virus for serological diagnosis. PLoS Neglected Tropical Diseases. 2022. DOI: https://doi.org/10.1371/journal.pntd.0010156

[5] Dunlop J, Szemiel AM, Navarro A, Wilkie G, Tong L, Modha S, et al.. Development of reverse genetics systems and investigation of host response antagonism and reassortment potential for Cache Valley and Kairi viruses, two emerging orthobunyaviruses of the Americas. PLoS Neglected Tropical Diseases. 2018. DOI: https://doi.org/10.1371/journal.pntd.0006884

[6] Ayers VB, Huang YS, Kohl A, Dunlop J, Hettenbach S, Park SL, et al.. Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus. Viral immunology. 2023. DOI: https://doi.org/10.1089/vim.2022.0103

[7] Ayers VB, Huang YS, Dunlop J, Kohl A, Brennan B, Higgs S, et al.. Replication Kinetics of a Candidate Live-Attenuated Vaccine for Cache Valley Virus in Aedes albopictus. Vector Borne and Zoonotic Diseases. 2022. DOI: https://doi.org/10.1089/vbz.2022.0053

[8] Dieme C, Ngo K, Tyler S, Maffei J, Zink S, Dupuis A, et al.. Role of Anopheles Mosquitoes in Cache Valley Virus Lineage Displacement, New York, USA. Emerging Infectious Diseases. 2022. DOI: https://doi.org/10.3201/eid2802.203810

[9] Dieme C, Maffei J, Diarra M, Koetzner CA, Kuo L, Ngo K, et al.. Aedes Albopictus and Cache Valley virus: a new threat for virus transmission in New York State. Emerging Microbes and Infections. 2022. DOI: https://doi.org/10.1080/22221751.2022.2044733

[10] Baker M, Hughes HR, Naqvi S, Yates K, Velez JO, McGuirk S, et al.. Reassortant Cache Valley virus associated with acute febrile, non-neurologic illness, Missouri.. Clinical Infectious Diseases. 2021. DOI: https://doi.org/10.1093/cid/ciab175

[11] Muller JA, López K, Escobar LE, Auguste AJ. Ecology and geography of Cache Valley virus assessed using ecological niche modeling. Parasites & Vectors. 2024. DOI: https://doi.org/10.1186/s13071-024-06344-z

[12] Ayers VB, Huang YS, Lyons AC, Park SL, Dunlop J, Unlu I, et al.. Infection and transmission of Cache Valley virus by Aedes albopictus and Aedes aegypti mosquitoes. Parasites & Vectors. 2019. DOI: https://doi.org/10.1186/s13071-019-3643-0

[13] Chan KK, Auguste AJ, Brewster C, Paulson S. Vector competence of Virginia mosquitoes for Zika and Cache Valley viruses. Parasites & Vectors. 2020. DOI: https://doi.org/10.1186/s13071-020-04042-0

[14] Ayers VB, Huang YS, Lyons AC, Park SL, Higgs S, Dunlop J, et al.. Culex tarsalis is a competent vector species for Cache Valley virus. Parasites & Vectors. 2018. DOI: https://doi.org/10.1186/s13071-018-3103-2

[15] Yang F, Chan KK, Marek P, Armstrong P, Liu P, Bova J, et al.. Cache Valley Virus in Aedes japonicus japonicus Mosquitoes, Appalachian Region, United States. Emerging Infectious Diseases. 2018. DOI: https://doi.org/10.3201/eid2403.161275

[16] Chung S, Cw L, Edwards JF, Gauer B, Collisson EW. Congenital malformations in sheep resulting from in utero inoculation of Cache Valley virus.. American Journal of Veterinary Research. 1990. DOI: https://doi.org/10.2460/ajvr.1990.51.10.1645

[17] Chung S, Cw L, Cw J, Ew C. Cache Valley virus infection in Texas sheep flocks.. Journal of the American Veterinary Medical Association. 1991. DOI: https://doi.org/10.2460/javma.1991.199.03.337

[18] Maxwell HE, Schwartz DW, Michael A, Waters K, Rush J. Cache Valley virus serologically identified in sheep with congenitally malformed lambs in Alabama.. American Journal of Veterinary Research. 2025. DOI: https://doi.org/10.2460/ajvr.25.06.0213

[19] Burke J, Wood E, Lee C, Carpenter A, Kojima N, Fagre AC, et al.. 57 Impact of Cache Valley Virus in an Arkansas sheep flock. Journal of Animal Science. 2024. DOI: https://doi.org/10.1093/jas/skae019.102

[20] Harvey J, Smith JS, Jackson N, Kreuder A, Dohlman T, Smith JD. Cache Valley virus as a cause of fetal abnormalities in a litter of three Boer kids. Veterinary Record Case Reports. 2019. DOI: https://doi.org/10.1136/vetreccr-2018-000725

[21] . malformations associated with in utero cache valley virus in sheep. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.76266

[22] Carpenter A, Kojima N, Dulski TM, Calvert AE, Burkhalter KL, Ballard JR, et al.. A One Health Approach to Investigating Cache Valley Virus, Arkansas, USA, July 2023. Emerging Infectious Diseases. 2025. DOI: https://doi.org/10.3201/eid3106.250052

[23] Bergevin MD, Ng V, Menzies P, Ludwig A, Mubareka S, Clow KM. Cache a Killer: Cache Valley virus seropositivity and associated farm management risk factors in sheep in Ontario, Canada. PLoS ONE. 2023. DOI: https://doi.org/10.1371/journal.pone.0290443

[24] Morris P, Wisnieski L, Smith S, Morris V, Hall K. Seroprevalence of Cache Valley virus in sheep population in the southcentral Appalachian region. American Association of Bovine Practitioners Conference Proceedings. 2026. DOI: https://doi.org/10.21423/aabppro20259390

[25] Campbell G, Mataczynski JD, Reisdorf E, Powell JWB, Martin D, Lambert A, et al.. Second Human Case of Cache Valley Virus Disease. Emerging Infectious Diseases. 2006. DOI: https://doi.org/10.3201/EID1205.051625

[26] Al-Heeti OM, Wu E, Ison M, Saluja RK, Ramsey G, Matkovic E, et al.. Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient with Meningoencephalitis. Clinical Infectious Diseases. 2022. DOI: https://doi.org/10.1093/cid/ciac566

[27] Yang Y, Qiu J, Snyder‐Keller A, Wu Y, Sun S, Sui H, et al.. Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy. American journal of hematology/oncology. 2018. DOI: https://doi.org/10.1002/ajh.25024

[28] Gill C, Beckham JD, Piquet A, Tyler K, Pastula D, Pastula D. Five Emerging Neuroinvasive Arboviral Diseases: Cache Valley, Eastern Equine Encephalitis, Jamestown Canyon, Powassan, and Usutu. Seminars in neurology. 2019. DOI: https://doi.org/10.1055/s-0039-1687839

[29] Wilson M, Suan D, Duggins A, Schubert RD, Khan LM, Sample H, et al.. A novel cause of chronic viral meningoencephalitis: Cache Valley virus. Annals of Neurology. 2017. DOI: https://doi.org/10.1002/ana.24982

[30] Byrd DS, Ananth AL, McDonald C, Atkinson T, Chiu C, Kimberlin D, et al.. Molnupiravir Treatment Associated With Clearance of Cache Valley Virus From Cerebrospinal Fluid in an Immunocompromised Child With Meningoencephalitis. Open Forum Infectious Diseases. 2026. DOI: https://doi.org/10.1093/ofid/ofag217

[31] López K, Wilson SN, Coutermash-Ott S, Tanelus M, Stone W, Porier D, et al.. Novel murine models for studying Cache Valley virus pathogenesis and in utero transmission. Emerging Microbes and Infections. 2021. DOI: https://doi.org/10.1080/22221751.2021.1965497

[32] Ortega-Soriano G, Plante JA, Fabela-Becerril VA, Gonzalez-Perez AL, Solís-Hernández M, Rafael G, et al.. Cache Valley virus isolation from a horse in Veracruz State, Mexico. Frontiers in Tropical Diseases. 2024. DOI: https://doi.org/10.3389/fitd.2024.1456666

[33] Rg M, Ch C, Gl P. Isolation of Cache Valley virus and detection of antibody for selected arboviruses in Michigan horses in 1980.. American Journal of Veterinary Research. 1987. DOI: https://doi.org/10.2460/ajvr.1987.48.07.1039

[34] Edwards JF, Hendricks K. Lack of serologic evidence for an association between Cache Valley Virus infection and anencephaly and other neural tube defects in Texas.. Emerging Infectious Diseases. 1997. DOI: https://doi.org/10.3201/eid0302.970215

[35] Goodman CH, Powers JA, Mikula S, Hughes HR, Biggerstaff B, Fitzpatrick K, et al.. Development of a Diagnostic IgM Antibody Capture ELISA for Detection of Anti-Cache Valley Virus Human IgM. American Journal of Tropical Medicine and Hygiene. 2024. DOI: https://doi.org/10.4269/ajtmh.24-0360

[36] Murat S. Potential role of peste des petits ruminants virus in small ruminant abortions.. The Veterinary Journal. 2024. DOI: https://doi.org/10.1016/j.tvjl.2024.106185

[37] Wang H, Nattanmai SM, Kramer L, Bernard K, Tavakoli NP. A duplex real-time RT-PCR assay for the detection of California serogroup and Cache Valley viruses. Diagnostic microbiology and infectious disease. 2009. DOI: https://doi.org/10.1016/j.diagmicrobio.2009.07.001

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.